Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome program

Encoded Therapeutics announced closing a Series F financing round that brought in $275 million.

The round was led by GV with participation from an undisclosed healthcare investor. The new capital will support development of the company’s precision genetic medicine targeting Dravet syndrome.

The funding highlights investor confidence in Encoded’s approach to treating the rare epileptic disorder.